FDMT 4D Molecular Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest 4D Molecular Therapeutics, Inc. (FDMT) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 18, 2026, a 10-Q quarterly report filed on May 7, 2026, an 8-K current report filed on July 20, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for 4D Molecular Therapeutics, Inc. (FDMT) (SEC CIK 1650648), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on 4D Molecular Therapeutics, Inc.
Ask AI about FDMT filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting FDMT positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on FDMT.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of 4D Molecular Therapeutics, Inc. (FDMT) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jul 20, 2026 | - | - | - |
8-K | Jun 29, 2026 | - | - | - |
8-K | Jun 22, 2026 | - | - | - |
8-K | May 7, 2026 | - | - | |
10-Q | May 7, 2026 | Mar 31, 2026 | - | |
8-K | Mar 30, 2026 | - | - | - |
8-K | Mar 18, 2026 | - | Analysis | - |
10-K | Mar 18, 2026 | Dec 31, 2025 | - | |
8-K | Jan 26, 2026 | - | - | |
8-K | Jan 7, 2026 | - | - | |
8-K | Dec 10, 2025 | - | - | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | - | |
10-Q | May 8, 2025 | Mar 31, 2025 | - | |
10-K | Feb 28, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | - | |
SC 13G | Nov 6, 2024 | - | - | |
SC 13G | Nov 4, 2024 | - | - | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | - | |
10-Q | May 9, 2024 | Mar 31, 2024 | - | |
10-K | Feb 29, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | - | |
SC 13G | Jun 5, 2023 | - | - | |
SC 13G | May 15, 2023 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate FDMT share value held by 13F filers tracked by SignalX, by quarter.
- Citadel Advisors LLC+246.2K (+347%)
- Dimensional Fund Advisors+228.0K (+77%)
- Bank of America Corp+141.6K (+17%)
- BlackRock+80.4K (+2%)
- Renaissance Technologies LLC+65.4K (+13%)
- Morgan Stanley327.3K (-49%)
- Two Sigma Investments213.2K (-63%)
- Raymond James Financial211.4K (-44%)
- Goldman Sachs Group97.5K (-2%)
- D.E. Shaw & Co87.8K (-79%)
- Vanguard Group Inc−3.09M
- JPMorgan Chase & Co−279.5K
- Invesco Ltd−153.1K
- Millennium Management−96.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 159 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest FDMT SEC filings in 2026?
4D Molecular Therapeutics, Inc. (FDMT) has filed a 10-K annual report on March 18, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 20, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did FDMT file its most recent 10-K annual report?
4D Molecular Therapeutics, Inc. (FDMT) filed its most recent 10-K annual report on March 18, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view FDMT 10-Q quarterly reports?
4D Molecular Therapeutics, Inc. (FDMT)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every FDMT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has FDMT filed recently?
4D Molecular Therapeutics, Inc. (FDMT)'s most recent 8-K was filed on July 20, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find FDMT insider trading activity (Form 4)?
SignalX aggregates every FDMT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does FDMT file with the SEC?
4D Molecular Therapeutics, Inc. (FDMT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new FDMT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for 4D Molecular Therapeutics, Inc. (FDMT).
What is FDMT's SEC CIK number?
4D Molecular Therapeutics, Inc. (FDMT)'s SEC CIK (Central Index Key) number is 1650648. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1650648 to look up all FDMT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of 4D Molecular Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 45+ filings.